Director (Audit & Supervisory Committee Member), Takeda Pharmaceutical Company Limited
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited 4502 · FY ending Mar 2026 · Director (Audit & Supervisory Committee Member) |
Own name | 19,756 | — | ¥5,663 | ¥112M | ¥4.0M |
Estate ¥115M = listed shares in own name ¥112M + other assets (est.) ¥3.1M
Total inheritance tax paid: ¥4.4M (3.8% of the estate).
| Heir | Inherits | Tax | After tax |
|---|---|---|---|
| Spouse | ¥57.5M | ¥0 | ¥57.5M |
| Each child | ¥28.8M | ¥2.2M | ¥26.6M |
Japanese inheritance tax, assuming the estate is split in statutory shares. A spouse pays no tax up to ¥160M or the statutory share, whichever is larger. Family size is not in the securities reports, so you can choose it (with no children, parents or siblings also become heirs, so the real figure differs). Business-succession deferrals, lifetime gifts, donations to foundations, debts and other reliefs are not reflected.